Gastrointestinal Cancer

Caroline Chung, MD, MSc, FRCPC, CIP, explores how AI in diagnostic imaging may help with accelerating scan acquisition and extracting subvisual features.

Caroline Chung, MD, MSc, FRCPC, CIP, discussed how AI is transforming radiotherapy, ranging from uniform dosing to personalized, immune-sparing strategies.

Data from 2 trials at the 2024 and 2025 ASCO Annual Meetings demonstrate the PD-L1/4-1BB bispecific antibody’s efficacy and safety in this population.

Toxicities with streptozotocin/5-fluorouracil and everolimus were comparable with other orally available chemotherapeutic schemes in this NET population.

Patients with pancreatic cancer who received up to 6 infusions of the multiantigen-targeted T cell product only experienced 1 treatment-related serious AE.

The Taiwan FDA has approved nivolumab/ipilimumab for patients with MSI-H/dMMR metastatic colorectal cancer based on data from CheckMate 8HW.

Data from the GALAXY study in Japan may inform future use of total neoadjuvant therapy among patients with rectal cancer in the US.

Any-grade AEs were comparable between cadonilimab and a PD-1 monoclonal antibody regimen in this population, and no difference in grade 3/4 AEs emerged.

The complicated nature of gastroesophageal cancer underscores the importance of collaboration between teams to safely treat patients with the disease.

Bodies like the NCCN must keep up with data related to ctDNA so that it can be incorporated in a measured manner, said Nicholas Hornstein, MD, PhD.

Circulating tumor DNA may particularly help adjuvant treatment decision-making in stage II colon cancer, according to Nicholas Hornstein, MD, PhD.

ACT5 of the PLAT study found radiotherapy dose escalation did not improve outcomes, safety, or QOL in patients with anal cancer.

In patients less likely to respond to neoadjuvant chemoradiation, postoperative adjuvant therapy may be a viable strategy in this ESCC group.

Surgeons and radiation oncologists can collaborate to discuss expected toxicity and surgical outcomes among patients with resectable gastric cancer.

Data from a phase 1/2a trial show no dose-limiting toxicities associated with ELC-100 among patients with neuroendocrine tumors.

PFS and response rates were proved to be meaningful among patients receiving zolbetuximab plus mFOLFOX6 and nivolumab for metastatic gastric/GEJ cancer.

Any-grade AEs were observed in 91% of the pembrolizumab arm vs 82% of the placebo arm, with AEs leading to death in 1% of patients in both arms.

Data from the HERIZON-GEA-01 trial may support zanidatamab as a promising new standard in HER2-positive gastroesophageal adenocarcinoma.

Early data from the ABC-HCC trial showed an improvement in median time to failure of strategy with atezolizumab/bevacizumab vs TACE in this HCC population.

Consistent with FGFR2 inhibition, lirafugratinib was well-tolerated among patients with FGFR2-mutated cholangiocarcinoma in the ReFocus trial.

The primary end point of ORR was met in the CAR-like T-cell arm for patients with gastric/GEJ cancer.

The safety profile of chemoradiotherapy with or without tislelizumab was acceptable among patients with gastric cancer or gastroesophageal junction cancer.

Data from the CRITICS-II trial support total neoadjuvant chemotherapy plus chemoradiotherapy as a preferred candidate for future study in this population.

Results from arm A of a phase 1/2 trial showed improved efficacy with multi-antigen targeted T cells plus frontline chemotherapy.

Patients with gastric cancer who were treated with a 3-drug antiemetic regimen had lower discontinuation rates following the first zolbetuximab dose.